Specify a stock or a cryptocurrency in the search bar to get a summary
Cadrenal Therapeutics, Inc. Common Stock
CVKDCadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida. Address: 822 A1A North, Ponte Vedra, FL, United States, 32082
Analytics
WallStreet Target Price
52.5 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CVKD
Dividend Analytics CVKD
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CVKD
Stock Valuation CVKD
Financials CVKD
Results | 2019 | Dynamics |